LT2050749T - Pirimidino darinys, kaip pi3k inhibitorius, ir jo panaudojimas - Google Patents

Pirimidino darinys, kaip pi3k inhibitorius, ir jo panaudojimas

Info

Publication number
LT2050749T
LT2050749T LTEP07792065.0T LT07792065T LT2050749T LT 2050749 T LT2050749 T LT 2050749T LT 07792065 T LT07792065 T LT 07792065T LT 2050749 T LT2050749 T LT 2050749T
Authority
LT
Lithuania
Prior art keywords
pi3k inhibitor
pyrimidine derivative
pyrimidine
derivative
pi3k
Prior art date
Application number
LTEP07792065.0T
Other languages
English (en)
Inventor
Nobuo Shimma
Hirosato Ebiike
Jun Ohwada
Hatsuo Kawada
Kenji Morikami
Mitsuaki Nakamura
Miyuki Yoshida
Nobuya Ishii
Masami Hasegawa
Shun Yamamoto
Kohei Koyama
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39032956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2050749(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of LT2050749T publication Critical patent/LT2050749T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
LTEP07792065.0T 2006-08-08 2007-08-07 Pirimidino darinys, kaip pi3k inhibitorius, ir jo panaudojimas LT2050749T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006216108 2006-08-08
JP2007118631 2007-04-27
PCT/JP2007/065396 WO2008018426A1 (fr) 2006-08-08 2007-08-07 Dérivé de pyrimidine comme inhibiteur de la PI3K et son utilisation

Publications (1)

Publication Number Publication Date
LT2050749T true LT2050749T (lt) 2018-01-10

Family

ID=39032956

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP07792065.0T LT2050749T (lt) 2006-08-08 2007-08-07 Pirimidino darinys, kaip pi3k inhibitorius, ir jo panaudojimas

Country Status (26)

Country Link
US (1) US8022205B2 (lt)
EP (1) EP2050749B1 (lt)
JP (1) JP4450857B2 (lt)
KR (1) KR101435692B1 (lt)
AR (1) AR062292A1 (lt)
AU (1) AU2007282535B9 (lt)
BR (1) BRPI0714908B8 (lt)
CA (1) CA2659604C (lt)
CL (1) CL2007002316A1 (lt)
CY (1) CY1119882T1 (lt)
DK (1) DK2050749T3 (lt)
ES (1) ES2657635T3 (lt)
HU (1) HUE035116T2 (lt)
IL (1) IL196601A (lt)
LT (1) LT2050749T (lt)
MX (1) MX2009001451A (lt)
MY (1) MY145385A (lt)
NO (1) NO342978B1 (lt)
NZ (1) NZ575274A (lt)
PE (1) PE20080527A1 (lt)
PL (1) PL2050749T3 (lt)
PT (1) PT2050749T (lt)
RU (1) RU2448109C2 (lt)
SI (1) SI2050749T1 (lt)
TW (1) TWI394758B (lt)
WO (1) WO2008018426A1 (lt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006613A (es) * 2006-12-21 2009-07-02 Nerviano Medical Sciences Srl Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
TW200938201A (en) * 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
KR20170128623A (ko) 2008-06-16 2017-11-22 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
CA2730271A1 (en) * 2008-07-07 2010-01-14 Xcovery Holding Company Llc Pi3k isoform selective inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
AU2009314544C1 (en) * 2008-11-11 2015-11-12 Xcovery Holding Company Llc PI3K/mTOR kinase inhibitors
NZ593536A (en) 2008-12-19 2013-07-26 Genentech Inc Quinoline derivatives and methods of use
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010114494A1 (en) * 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
EP3072890B1 (en) 2009-07-07 2018-10-17 MEI Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
NZ626650A (en) * 2009-09-09 2015-12-24 Celgene Avilomics Res Inc Pi3 kinase inhibitors and uses thereof
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011109059A1 (en) 2010-03-01 2011-09-09 Gtx, Inc. Compounds for treatment of cancer
US8912178B2 (en) 2010-05-19 2014-12-16 Xcovery Holdings Company, LLC mTOR selective kinase inhibitors
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
EP2673269A1 (en) * 2011-02-09 2013-12-18 F.Hoffmann-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
PT3141548T (pt) * 2011-07-05 2020-07-10 Vertex Pharma Processos e intermediários para a produção de azaindóis
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
KR102371532B1 (ko) 2011-09-02 2022-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
US20130123255A1 (en) * 2011-11-10 2013-05-16 Chugai Seiyaku Kabushiki Kaisha Combination of a pi3k inhibitor and a mek inhibitor
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
NO2868660T3 (lt) 2012-07-02 2018-05-26
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
TR201812261T4 (tr) * 2012-11-01 2018-11-21 Infinity Pharmaceuticals Inc Pi3 ki̇naz i̇zoform modülatörleri̇ i̇le kanser tedavi̇si̇
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
SG11201602446VA (en) * 2013-10-16 2016-05-30 Shanghai Yingli Pharm Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
CN106536753B (zh) 2014-04-04 2020-07-21 中美冠科生物技术（太仓）有限公司 用于确定对mek/erk抑制剂的应答性的方法
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016136928A1 (ja) 2015-02-27 2016-09-01 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
NZ734993A (en) 2015-02-27 2024-03-22 Incyte Holdings Corp Salts of pi3k inhibitor and processes for their preparation
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP6991158B2 (ja) * 2016-05-18 2022-02-10 ピクール セラピューティクス アーゲー 神経障害の治療法
JP6975514B2 (ja) 2016-07-08 2021-12-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 縮合ピリミジン誘導体
JP6980751B2 (ja) 2016-07-14 2021-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 縮合ピリミジン誘導体
IT201600092469A1 (it) * 2016-09-14 2018-03-14 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione di Blonanserina
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018065340A1 (en) 2016-10-04 2018-04-12 F. Hoffmann-La Roche Ag Bicyclic heteroaryl derivatives
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
SG11202001258UA (en) 2017-08-14 2020-03-30 Mei Pharma Inc Combination therapy
WO2019101984A1 (en) 2017-11-27 2019-05-31 F. Hoffmann-La Roche Ag Pyrimidine derivatives
WO2021247862A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Bicyclic heteroarenes and methods of their use
TW202220661A (zh) 2020-08-07 2022-06-01 德商柏林化學股份公司 包含pi3k抑制劑之經改良醫藥調配物
JP2024515062A (ja) 2021-04-09 2024-04-04 イミュニック アクチェンゲゼルシャフト 重水素化ｄｈｏｄｈ阻害剤
WO2023107623A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Bicyclic heteroarenes and methods of their use
CA3240381A1 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Pyrimidines and methods of their use
WO2024023766A1 (en) 2022-07-28 2024-02-01 Berlin-Chemie Ag P13k inhibitor combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325268A (ja) 1986-02-24 1996-12-10 Mitsui Petrochem Ind Ltd ピロロ〔３，４−ｄ〕ピリミジン誘導体
US4959368A (en) * 1986-02-24 1990-09-25 Mitsui Petrochemical Industries Ltd. Therapeutic agent for neurological diseases
US5378700A (en) * 1989-10-11 1995-01-03 Teijin Limited Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
EP2404603A1 (en) * 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
WO2004043367A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
CA2507100C (en) * 2002-11-21 2012-10-09 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
AU2004235907B2 (en) 2003-05-05 2007-08-30 F. Hoffmann La-Roche Ag Fused pyrimidine derivatives with CRF activity

Also Published As

Publication number Publication date
DK2050749T3 (en) 2018-01-08
MY145385A (en) 2012-01-31
EP2050749A1 (en) 2009-04-22
JPWO2008018426A1 (ja) 2009-12-24
BRPI0714908B1 (pt) 2020-10-13
PT2050749T (pt) 2018-01-02
AR062292A1 (es) 2008-10-29
NZ575274A (en) 2010-11-26
CA2659604C (en) 2015-04-28
EP2050749B1 (en) 2017-11-22
SI2050749T1 (en) 2018-04-30
CL2007002316A1 (es) 2008-02-01
PL2050749T3 (pl) 2018-03-30
IL196601A (en) 2015-03-31
AU2007282535A1 (en) 2008-02-14
IL196601A0 (en) 2009-11-18
TWI394758B (zh) 2013-05-01
KR101435692B1 (ko) 2014-09-01
CA2659604A1 (en) 2008-02-14
US8022205B2 (en) 2011-09-20
TW200817411A (en) 2008-04-16
PE20080527A1 (es) 2008-07-09
AU2007282535B2 (en) 2013-05-30
WO2008018426A1 (fr) 2008-02-14
BRPI0714908B8 (pt) 2021-05-25
KR20090047462A (ko) 2009-05-12
JP4450857B2 (ja) 2010-04-14
AU2007282535B9 (en) 2013-06-20
BRPI0714908A2 (pt) 2013-05-28
US20100069629A1 (en) 2010-03-18
RU2009108328A (ru) 2010-09-20
CY1119882T1 (el) 2018-06-27
MX2009001451A (es) 2009-02-18
NO20084533L (no) 2009-01-09
ES2657635T3 (es) 2018-03-06
NO342978B1 (no) 2018-09-17
RU2448109C2 (ru) 2012-04-20
EP2050749A4 (en) 2011-03-30
HUE035116T2 (hu) 2018-05-02

Similar Documents

Publication Publication Date Title
PT2050749T (pt) Derivado de pirimidina como inibidador de pi3k e sua utilização
HUS2200052I1 (hu) Imidazotriazinok és imidazopirimidinek mint kinázgátlók
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
ZA200901593B (en) Pyrimidines derivatives and their use as kinase inhibitors
HK1123296A1 (en) Pyrazine derivatives and use as pi3k inhibitors
HK1119696A1 (en) Pyridopyrimidinone inhibitors of pi3k pi3k
EP1999130A4 (en) Pyridopyrimidine derivatives and their use as PDE4 inhibitors
HK1144306A1 (zh) 激酶抑制劑及其用途
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
EP2239261A4 (en) PYRROLOPYRIMIDINE DERIVATIVE FOR USE AS A PI3K INHIBITOR AND USE THEREOF
IL193693A0 (en) Purine compounds and methods of use thereof
EP2084139A4 (en) OXAZOLIDINIUM COMPOUNDS AND USE AS HYDRATINE HIBITORS
EP2077262A4 (en) IMINOPYRIDINE DERIVATIVES AND THEIR USE
ZA200900907B (en) Pyrimidine derivative as P13K inhibitor and use thereof
EP2083826A4 (en) PYRIMIDINE DERIVATIVES AS POSH AND POSH-AP HEMMER
ZA200809113B (en) Pyrimidine derivatives as p13k inhibitors
ZA200807956B (en) Purine compounds and methods of use thereof
TH0701003936B (th) อนุพันธ์พิริมิดีนเป็นสารยับยั้ง pi3k และการใช้ของสารนั้น
IL198627A0 (en) Pyrimidine derivatives as posh and posh-ap inhibitors